ArticleFertility and sterility2011
A disintegrin and metalloprotease protein-12 as a novel marker for the diagnosis of ectopic pregnancy.
Article in Fertility and sterility, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer.Journal of proteomics · 2013Trial
- Identification and verification of plasma protein biomarkers that accurately identify an ectopic pregnancy.Clinical proteomics · 2023Article
- Validation of a multiple marker test for early pregnancy outcome prediction.Journal of assisted reproduction and genetics · 2023Article
- [Talin1 is highly expressed in the fallopian tube and chorionic villi to promote trophoblast invasion in tubal pregnancy].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Endogenous Retroviruses Drive Lineage-Specific Regulatory Evolution across Primate and Rodent Placentae.Molecular biology and evolution · 2021Article
- Predicting first trimester pregnancy outcome: derivation of a multiple marker test.Fertility and sterility · 2016Article
- Utility of proteomics in obstetric disorders: a review.International journal of women's health · 2015Review
- Maternal serum disintegrin and metalloprotease protein-12 in early pregnancy as a potential marker of adverse pregnancy outcomes.PloS one · 2014Article
- Biomarkers for ectopic pregnancy and pregnancy of unknown location.Fertility and sterility · 2013Review
- Comparison of the diagnostic values of circulating steroid hormones, VEGF-A, PIGF, and ADAM12 in women with ectopic pregnancy.Journal of translational medicine · 2013Article
- Article
- Validation of a clinical risk scoring system, based solely on clinical presentation, for the management of pregnancy of unknown location.Fertility and sterility · 2013Article
- Serum biomarkers for detecting ectopic pregnancy.Clinical obstetrics and gynecology · 2012Review
- A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer.Journal of proteome research · 2012Article
- Evaluation of ADAM-12 as a diagnostic biomarker of ectopic pregnancy in women with a pregnancy of unknown location.PloS one · 2012Article
- Rapid verification of candidate serological biomarkers using gel-based, label-free multiple reaction monitoring.Journal of proteome research · 2011Article
- Laboratory models for studying ectopic pregnancy.Current opinion in obstetrics & gynecology · 2011Review
- Overview of ectopic pregnancy diagnosis, management, and innovation.Women's health (London, England)Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate the performance of a novel biomarker, a disintegrin and metalloprotease-12 (ADAM-12), to differentiate an ectopic pregnancy (EP) from normal intrauterine pregnancies (IUPs).
designCase-control study.
settingThree urban academic centers. PATIENT(S): Women who were seen in the emergency department with pain or bleeding in the first trimester of pregnancy. INTERVENTION(S): Sera from women with diagnosed EP or IUP were evaluated via proteomics and an ADAM-12 dissociation-enhanced lanthanide fluoroimmunoassay. MAIN OUTCOME MEASURE(S): Differences between groups, area under the receiver operating curve, sensitivity, and specificity. RESULT(S): Via a proteomics evaluation, we found a statistically significant decrease in ADAM-12 in the sera of patients with EP, which we confirmed in a larger group of 199 patients (median IUP 18.6 ng/mL versus median EP 2.5 ng/mL with good discrimination between the groups as assessed by receiver operating characteristics [area under the curve = 0.82]). At a low cut-point, the sensitivity was 70% and specificity 84%, but, at a higher cut-point optimizing sensitivity, the ADAM-12 test demonstrated a sensitivity of 97%. CONCLUSION(S): ADAM-12 is a promising marker for the diagnosis of EP in women with symptoms in the first trimester, validating the proteomics findings. Further studies in additional patient populations and in combination with other biomarkers are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.